Duloxetine Hcl Articles
Global pain management drugs market to see moderate growth as generic share continues to rise
24 November 2011
Double dose of woes for Eli Lilly, as it drops Ph III AD drug semagacestat and FDA panel could say no to expanding use of Cymbalta
18 August 2010
UK’s NICE sets national standard for neuropathic pain drug treatments in non-specialist NHS settings; guidance on angina
25 March 2010
Neuropathic pain - brighter future for pipeline drugs with market to double in value to $5.2 billion
17 February 2010
US FDA warns four drugmakers on inaccurate promotion
13 January 2010
World fibromyalgia syndrome market to grow at a CAGR of 9.2% for the next seven years, reaching $1.8 billion by 2015, forecasts Global Data
11 January 2010
Eli Lilly outlines innovation strategy, sets 2010 financial guidance, but disappoints Wall Street
11 December 2009
Regulatory approval briefs: Betaferon in China; new use for Lilly’s Cymbalta in USA; update on telavancin
1 December 2009
Generic erosion of atypical antipsychotics will cause the bipolar disorder drug market to decline by over $1 billion through 2018
6 November 2009
Batch of approvals and positive opinions from EU’s CHMP
26 October 2009
Eli Lilly 3rd quarter 2009 beats forecasts, raises guidance
22 October 2009
Patent protection for key blockbuster depression drugs will drive growth in Europe and Japan, but not USA, says DR report
18 August 2009
Lilly resubmits Cymbalta sNDA for
5 June 2009
Lilly's 1st-qtr profit jumps 23.6% to $1.31B
29 April 2009
Winston Pharma gets orphan status for civamide
2 March 2009
Lexapro and Zoloft are "best" antidepressants
9 February 2009
Cymbalta cuts pain in 65% of OA patients
9 February 2009
Lilly swings to loss on ImClone acquisition
9 February 2009
Cymbalta delays onset of depression episode
22 December 2008
Cymbalta chronic pain sNDA to be resubmitted
8 December 2008
IMPAX sued by Lilly over Cymbalta
1 December 2008
Lilly swings into loss in 3rd qtr on legal costs
3 November 2008
Cymbalta reduces chronic lower back pain
8 September 2008
Lilly/Boehringer's duloxetine reduces DPNP
1 September 2008
EMEA approves Cymbalta for GAD
1 September 2008
Lilly's 2nd-qtr rise hides coming challenges
4 August 2008
Cymbalta gets nod for GAD in European
7 July 2008
FDA clears Cymbalta for fibromyalgia, 4th appro
23 June 2008
Lilly submits Cymbalta sNDA for chronic pain
9 June 2008
Lilly has good 1Q sales but still disappoints
28 April 2008
Lilly's 4th qtr recovers from Zyprexa settlement
4 February 2008
Lilly hits back at data suppression claims
28 January 2008
US Congress to re-open drug import debate
28 January 2008
Japan stock market week toJan 14, 2008
21 January 2008
Additional indication for Lilly's Cymbalta
10 December 2007
Eli lilly sees 3rd qtr net income climb 6% as sales jump 19% to $4.6B, raises full-year guidance
29 October 2007
Cymbalta cuts fibromyalgia pain severity
3 September 2007
Lilly's 2nd-qtr 20% sales hike beats estimates
30 July 2007
Less pain for depressives switched to duloxetine
4 June 2007
Cymbalta improves SDS score in GAD patients
4 June 2007
Lilly's 1st-qtr 2007 earnings drop 39%
23 April 2007
Boehringer Ingelheim's duloxetine addresses emotional symptoms and pain in depression trial
26 March 2007
Lilly to buy Hypnion for access to drugs
12 March 2007
US FDA approves Lilly's Cymbalta in GAD
5 March 2007
Lilly's income down 81%, but shares up 1.5%
12 February 2007
Lilly reiterates 2006/07 guidance, disappoints
18 December 2006
Eli Lilly will not cut back in France
20 November 2006
Lilly's 3rd-qtr 2006 profit rises 10% on Zyprexa
30 October 2006
EASD panels recommend insulin acceptance, and highlight shortfalls in DPNP therapy
25 September 2006
Israeli basket update c'tee recommends another 16 new technologies
4 September 2006
Lilly swings to 2nd-qtr 2006 EPS of $0.76
31 July 2006
Cymbalta: less impact on sex than Lexapro
29 May 2006
Eli Lilly submits Cymbalta sNDA to US FDA
15 May 2006
Correction: Eli Lilly
1 May 2006
Eli Lilly profit up 6% in 1st-qtr 2006
1 May 2006
Cymbalta performs well in anxiety study
3 April 2006
Lilly's Cymbalta relieves core GAD symptoms
3 April 2006
Eli Lilly and BI alter Yentreve/AriClaim deal
20 February 2006
Eli Lilly will submit sNDA on Cymbalta for GAD
19 December 2005
US FDA posts DSOB meeting summary
15 August 2005
Lilly swings to loss in 2nd qtr on settlement
1 August 2005
Data support Eli Lilly's Cymbalta's role in DPNP
20 June 2005
Lilly's Cymbalta: strong performance in elderly
6 June 2005
EMEA warning over SSRIs, SNRIs in children
26 April 2005
BI/Eli Lilly's Yentreve effective in SUI
18 April 2005
Positive opinion for Lilly's Cymbalta
28 February 2005
US volume Rx sales rise 8.3% in 2004
21 February 2005
New product launches in 2004
31 January 2005
EC OKs Cymbalta for major depression
10 January 2005
Quintiles' 3rd-qtr revenues rise 9%
22 November 2004
Cymbalta on track in EU for depression
27 September 2004
BI/Lilly's Yentreve available in Europe
20 September 2004
BI 1st-half sales up 7%
23 August 2004
BI/Lilly's Yentreve cleared for SUI in EU
23 August 2004
Lilly's Cymbalta OKed for depression by FDA
9 August 2004
Stock Commentary - New York
19 July 2004
Elan to make duloxetine for Lilly
21 June 2004
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
